Potential application of temozolomide in mesenchymal stem cell-based trail gene therapy against malignant glioma

Stem Cells Translational Medicine

Volumn 3, Issue 2, 2014, Pages 172-182

  Kim, Seong Muk ^a   Woo, Ji Sun ^b   Jeong, Chang Hyun ^b   Ryu, Chung Heon ^a   Jang, Jae Deog ^c   Jeun, Sin Soo ^a,b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Glioma; Mesenchymal stem cells; Temozolomide; Trail

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE MARROW BIOPSY; CELL ISOLATION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MOUSE; NONHUMAN; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TUMOR REGRESSION; WESTERN BLOTTING; YOUNG ADULT;

GLIOMA; MESENCHYMAL STEM CELLS; TEMOZOLOMIDE; TRAIL;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; GENETIC THERAPY; GLIOMA; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MIDDLE AGED; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84894045200     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0132     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
3. Kuijlen JM, Bremer E, Mooij JJ et al. Review: On TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 2010;36:168-182.
4. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
5. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
6. Wiley S.R, Schooley K., Smolak P.J.,et al. Identificationand characterization of anewmember of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
7. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Ther 2006;13:225-233.
8. Hamada H, Kobune M, Nakamura K et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005;96:149-156.
9. Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68: 9614-9623.
10. Sasportas LS, Kasmieh RK, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822-4827.
11. Menon LG, Kelly K, Yang HW et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. STEM CELLS 2009;27:2320-2330.
12. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007;25:4505-4506.
13. Rieger J, Frank B, Weller M et al. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem 2007;20:23-34.
14. Mahalingam D, Szegezdi E, Keane M et al. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35:280-288.
15. Kim SM, Oh JH, Park SA et al. Irradiation enhances the tumor tropism and therapeutic potentialof tumornecrosis factor-relatedapoptosisinducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. STEM CELLS 2010;28:2217-2228.
16. Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382.
17. Uzzaman M, Keller G, Germano IM. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg 2007;106:646-651.
18. Saito R, Bringas JR, Panner A et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004;64:6858-6862.
19. Hingtgen S, Ren X, Terwilliger E et al. Targeting multiple pathways in gliomas with stem cellandviraldeliveredS-TRAILandTemozolomide. Mol Cancer Ther 2008;7:3575-3585.
20. Kim SM, Kim DS, Jeong CH et al.CXCchemokine receptor 1 enhances the ability of human umbilical cord blood-derivedmesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 2011;407:741-746.
21. Kim CY, Jeong M, Mushiake H et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006;13:330-338.
22. Kim SW, Kim SJ, Park SH et al. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res 2013;19:415-427.
23. Stadel D, Mohr A, Ref C et al. TRAILinduced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010;16:5734-5749.
24. Haag C, Stadel D, Zhou S et al. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011;60:225-237.
25. Mohr A, Albarenque SM, Deedigan L et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. STEM CELLS 2010;28: 2109-2120.
26. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosisinducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-3630.
27. Kelley SK, Harris LA, Xie D et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics,andsafety. JPharmacolExpTher 2001;299:31-38.
28. Griffith TS, Stokes B, Kucaba TA et al. TRAIL gene therapy: From preclinical development to clinical application. Curr Gene Ther 2009;9:9-19.
29. Grisendi G, Bussolari R, Cafarelli L et al. Adipose-derivedmesenchymalstemcellsasstable source of tumor necrosis factor-related apoptosisinducing liganddelivery for cancer therapy. Cancer Res 2010;70:3718-3729.
30. Soria JC, Smit E, Khayat D et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010;28:1527-1533.
31. Camidge DR, Herbst RS, Gordon MS et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256-1263.
32. Kim SM, Woo JS, Jeong CH et al. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res 2012;72:4807-4817.
33. Bagci-Onder T, Wakimoto H, Anderegg M et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011;71: 154-163.
34. Hendruschk S, Wiedemuth R, Aigner A et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011; 13:1074-1089.
35. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-237.
36. Ding L, Yuan C, Wei F et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 2011; 29:511-520.
37. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195.
38. Deveraux QL, Takahashi R, Salvesen GS et al. X-linked IAP is a direct inhibitor of celldeath proteases. Nature 1997;388:300-304.